Position in ADMA
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$5,607
-$4,385 QoQ
Shares Held
670
-39.6% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#283
of 320 holders
Holding Since
Jun 2023
10 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ADMA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Coppell Advisory Solutions LLC holds $1,491,155 across 13 Biotechnology names. ADMA ranks #6 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TVTX |
Travere Therapeutics, Inc.
|
12,304 | $698,990 | |
| 2 | ANAB |
Anaptysbio, Inc
|
3,638 | $245,565 | |
| 3 | INCY |
Incyte Corp
|
2,057 | $233,181 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
436 | $216,573 | |
| 5 | CORT |
Corcept Therapeutics Inc
|
962 | $83,645 | |
| 6 | ADMA |
Adma Biologics, Inc.
This page
|
670 | $5,607 | |
| 7 | NTLA |
Intellia Therapeutics, Inc.
|
134 | $2,267 | |
| 8 | AGIO |
Agios Pharmaceuticals, Inc.
|
59 | $2,189 |
All Filings in ADMA
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,607 | 670 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $9,992 | 1,109 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $9,721 | 533 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $12,138 | 828 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $18,027 | 990 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $18,787 | 947 | Shares | Sole | 2025-05-16 | |
| 2024-12-31 | $10,221 | 596 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $16,751 | 838 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $19,989 | 1,788 | Shares | Sole | 2024-08-15 | |
| 2023-06-30 | $1,346 | 365 | Shares | Sole | 2023-08-17 | |
| No filing history on record for this holder in this stock. | ||||||